| Unique ID issued by UMIN | UMIN000032888 |
|---|---|
| Receipt number | R000037494 |
| Scientific Title | Investigation of biomarkers for diagnosis and treatment of pulmonary hypertension. |
| Date of disclosure of the study information | 2018/07/01 |
| Last modified on | 2020/06/08 09:53:31 |
Investigation of biomarkers for diagnosis and treatment of pulmonary hypertension.
Biomarkers for pulmonary hypertension.
Investigation of biomarkers for diagnosis and treatment of pulmonary hypertension.
Biomarkers for pulmonary hypertension.
| Japan |
Pulmonary hypertension
| Cardiology | Pneumology | Clinical immunology |
Others
NO
Objectives of this study is to establish the biomarkers for early daiagnosis and useful treatment of pulmonary hypertension.
Others
Verification of usefulness of serum periostin and blood - derived exosomes as a biomarker in pulmonary hypertension.
level of serum periostin.
Profile of microRNA and protein in exosome from blood sample.
Observational
| 20 | years-old | <= |
| 100 | years-old | >= |
Male and Female
Patient who is diagnosed as pulmonary hypertension including from group 1 to 5 in international classification.
Patient who has not undergone right heart catheterization and has not reached definite diagnosis of pulmonary hypertension.
50
| 1st name | Tetsutaro |
| Middle name | |
| Last name | Nagaoka |
Juntendo University
Division of respiratory medicine
113-8431
Nerima-ku
0358021063
jnagaoka@juntendo.ac.jp
| 1st name | Tetsutaro |
| Middle name | |
| Last name | Nagaoka |
Juntendo University
Division of respiratory medicine
113-8431
3-1-3 Hongo Bunkyo-ku, Tokyo, Japan
03-5802-1063
jnagaoka@juntendo.ac.jp
Juntendo University
Juntendo university
Other
Juntendo University Hospital
3-1-3 Hongo
+81358021063
jnagaoka@juntendo.ac.jp
NO
| 2018 | Year | 07 | Month | 01 | Day |
Unpublished
Open public recruiting
| 2018 | Year | 05 | Month | 31 | Day |
| 2018 | Year | 05 | Month | 31 | Day |
| 2018 | Year | 06 | Month | 01 | Day |
| 2022 | Year | 12 | Month | 31 | Day |
We verify the correlation between severity of pulmonary hypertension and biomarkers in each group.
| 2018 | Year | 06 | Month | 06 | Day |
| 2020 | Year | 06 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037494